Apomorphine: An update of clinical trial results

International Journal of Impotence Research

Volumn 12, Issue , 2000, Pages S67-S73

  Heaton, J P W ^a  

^a QUEEN S UNIVERSITY   (Canada)

Author keywords

Apomorphine; Central nervous system; Dopaminergic; Erection

Indexed keywords

APOMORPHINE;

ADULT; AGED; CLINICAL TRIAL; CONFERENCE PAPER; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG FORMULATION; ERECTILE DYSFUNCTION; HUMAN; MAJOR CLINICAL STUDY; MALE; NAUSEA; PENIS ERECTION; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; SEXUAL INTERCOURSE;

ADOLESCENT; ADULT; AGED; APOMORPHINE; CLINICAL TRIALS, PHASE III; COITUS; CROSS-OVER STUDIES; DOPAMINE AGONISTS; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; HUMANS; IMPOTENCE; MALE; MIDDLE AGED; NAUSEA; PENILE ERECTION; RESEARCH DESIGN; SAFETY; TIME FACTORS; TREATMENT OUTCOME;

EID: 0033772321     PISSN: 09559930     EISSN: 14765489     Source Type: Journal    
DOI: 10.1038/sj.ijir.3900581     Document Type: Article

References (16)

1. Linet OI, Ogrinc FG. Efficacy and safety of intracavernosal alprostadil in men with erectile dysfunction. The Alprostadil Study Group. New Engl J Med 1996; 334: 873-877.
2. NIH Consensus Development Panel on Impotence. JAMA 1993;270:83-90.
3. Padina-Nathan H et al. Treatment of men with erectile dysfunction with transurethral alprostadil. Medicated Urethral System for Erection (MUSE) Study Group. New Engl J Med 1997; 336: 1-7.
4. Goldstein I et al. Oral sildenafil in the treatment of erectile dysfunction. Sildenafil Study Group. New Engl J Med 1998; 338: 1397-1404.
5. O’Leary MP et al. A brief male sexual function inventory for urology. Urology 1995; 46: 697-706.
6. Rosen RC et al. The international index of erectile function (IIEF): A multidimensional scale for assessment of erectile dysfunction. Urology 1997; 49: 822-830.
7. Heaton JP et al. Recovery of erectile function by the oral administration of apomorphine. Urology 1995; 45: 200-206.
8. McKenna KE. Central control of penile erection. Int J Impot lies 1998; 10(Suppl 1); S25-34.
9. Rajfer J et al. Nitric oxide as a mediator of relaxation of the corpus cavernosum in response to nonadrenergic, noncholi-nergic neurotransmission. New Engl J Med 1992; 326: 90-94.
10. Boolell M et al. Sildenafil: An orally active type 5 cyclic GMP-specific phosphodiesterase inhibitor for the treatment of penile erectile dysfunction. Int J Impot Res 1996; 8: 47-52.
11. Szechtman H et al. Sensitization and tolerance to apomorphine in men: Yawning, growth hormone, nausea, and hyperthermia. Psychiat lies 1988; 23: 245-55.
12. Wilson PW, Culleton BF. Epidemiology of cardiovascular disease in the United Slates. Am J Kidney Dis 1998; 32(5 Suppl 3); S56-65.
13. Johannes CB et al. Incidence of erectile dysfunction in men 40-69y old: Longitudinal results from the Massachusetts Male Aging Study. J Urol 2000; 163: 460-463.
14. Feldman HA et al. Erectile dysfunction and coronary risk factors: Prospective results from the Massachusetts Male Aging Study. Prev Med 2000; 30; 328-338.
15. Muller JE et al. Triggering myocardial infarction by sexual activity. Low absolute risk and prevention by regular physical exertion. Determinants of Myocardial Infarction Onset Study Investigators. JAMA 1996; 275: 1405-1409.
16. Feldman HA et al. Impotence and its medical and psychosocial correlates: Results of the Massachusetts Male Aging Study. J Urol 1994; 151: 54-61.